Načítá se...
Emerging serine-threonine kinase inhibitors for treating ovarian cancer
INTRODUCTION: Ovarian cancer is the leading cause of gynecologic cancer death, owing to high rates of incurable, recurrent disease after initial treatment. Serine threonine kinases (STKs) have been proposed as potential therapeutic targets in ovarian cancer because of their role in the initiation an...
Uloženo v:
| Vydáno v: | Expert Opin Emerg Drugs |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7526049/ https://ncbi.nlm.nih.gov/pubmed/31755325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728214.2019.1696773 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|